Drug expenditure of high-cost patients and their characteristics in Finland

被引:16
作者
Saastamoinen, Leena K. [1 ]
Verho, Jouko [1 ]
机构
[1] Social Insurance Inst, Res Dept, Helsinki 00101, Finland
关键词
Drug; Pharmaceutical; Expenditure; Cost; Distribution; Medicine user; High-cost patients; Cost containment; HEALTH-CARE EXPENDITURES; PRESCRIPTION; MEDICATION; THERAPY; POLYPHARMACY; POPULATION; REGISTER; POLICIES; GROWTH; ADULTS;
D O I
10.1007/s10198-012-0393-8
中图分类号
F [经济];
学科分类号
02 ;
摘要
Little information exists on how constantly growing pharmaceutical expenditures are distributed in large representative samples of national populations in Western countries. This study analyzes the distribution of pharmaceutical expenditures in ambulatory care and explores the basic characteristics of the high-cost drug users. Reimbursed prescription drug purchases in 2009 were derived from the National Prescription Register for a 50 % sample of the adult Finnish population. The high-cost users who were among the top 5 % in terms of drug expenditures were identified based on annual drug costs. The distribution of pharmaceutical costs is strongly skewed in Finland; only 5 % of the population accounts for about half of the costs. These high-cost drug users were older than the low-cost drug users, with more than one-fourth of them being over 75 years old. The high-cost drug users used, on average, more drugs than the low-cost drug users, but approximately 15 % of them used only 1-5 drugs. Almost 50 % of the high-cost drug users used more than 10 drugs per year. They had chronic diseases more often than the low-cost drug users, especially uremia requiring dialysis, post-transplant conditions, severe anemia associated with chronic renal failure and multiple sclerosis were common among the high-cost users. The skewness of the cost distribution indicates a need for more patient-specific cost-containment methods, and the high number of drugs in the high-cost group calls for exploring the possibilities of disease management and patient monitoring techniques in cost containment.
引用
收藏
页码:495 / 502
页数:8
相关论文
共 33 条
  • [1] Pharmaceutical policies:: effects of reference pricing, other pricing, and purchasing policies
    Aaserud, M.
    Dahlgren, A. T.
    Kosters, J. P.
    Oxman, A. D.
    Ramsay, C.
    Sturm, H.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02):
  • [2] [Anonymous], ATC DDD IND 2011
  • [3] [Anonymous], 2010, FINN STAT MED 2009
  • [4] Pharmaceutical policies: effects of cap and co-payment on rational drug use
    Austvoll-Dahlgren, A.
    Aaserud, M.
    Vist, G.
    Ramsay, C.
    Oxman, A. D.
    Sturm, H.
    Koesters, J. P.
    Vernby, A.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01):
  • [5] The concentration of health care expenditures, revisited
    Berk, ML
    Monheit, AC
    [J]. HEALTH AFFAIRS, 2001, 20 (02) : 9 - 18
  • [6] CHANG C, 2011, FILM COMMENT, V47, P72
  • [7] Drug copayment and adherence in chronic heart failure: Effect on cost and outcomes
    Cole, J. Alexander
    Norman, Heather
    Weatherby, Lisa B.
    Walker, Alexander M.
    [J]. PHARMACOTHERAPY, 2006, 26 (08): : 1157 - 1164
  • [8] Characteristics of older adults who meet the annual prescription drug expenditure threshold for Medicare medication therapy management programs
    Daniel, Gregory W.
    Malone, Daniel C.
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2007, 13 (02): : 142 - 154
  • [9] Polypharmacy in Nursing Home Residents in the United States: Results of the 2004 National Nursing Home Survey
    Dwyer, Lisa L.
    Han, Beth
    Woodwell, David A.
    Rechtsteiner, Elizabeth A.
    [J]. AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2010, 8 (01) : 63 - 72
  • [10] European healthcare policies for controlling drug expenditure
    Ess, SM
    Schneeweiss, S
    Szucs, TD
    [J]. PHARMACOECONOMICS, 2003, 21 (02) : 89 - 103